Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
The PPiP2 study aims to investigate the prevalence of autoimmune antibodies in patients with psychosis and identify people with psychosis and anti-neuronal membrane antibodies to take part in the SINAPPS2 trial.
The immune system normally controls our ability to fight infection. If the immune system goes wrong it may attack our own body, causing diseases called ‘autoimmune’ diseases. It has been discovered that some of these autoimmune diseases can affect the brain, and in the early stages of the disease they can manifest through symptoms of psychosis.
We can diagnose some of these autoimmune diseases using blood tests to detect specific antibodies. We are specifically interested in antibodies that may be the cause of symptoms of psychosis and possibly in some cases of schizophrenia.